STA 36

Drug Profile

STA 36

Alternative Names: STA36

Latest Information Update: 22 Jul 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SunTen Phytotech
  • Developer Lumosa Therapeutics
  • Class Antiasthmatics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Allergic asthma

Most Recent Events

  • 22 Jul 2015 Discontinued - Phase-II for Allergic asthma (Adjuvant therapy) in Taiwan (unspecified route)
  • 31 Jan 2008 Taiwan Department of Health approves IND application for STA 36 in asthma
  • 12 Jul 2006 Phase-II clinical trials in Allergic asthma (Adjuvant therapy) in Taiwan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top